Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05638412 · ClinicalTrials.gov registry record · NA

Investigating the Impact of JASPER Behavioral Therapy in Children With Down Syndrome

A NA study of Down Syndrome, sponsored by Boston Children's Hospital.

Active
Registry status
NA
Development phase
57
Enrollment target
1
Study location

NCT05638412: Active NA study of Down Syndrome, sponsored by Boston Children's Hospital.

NCT05638412 is a NA study of Down Syndrome that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 57 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05638412, a NA study of Down Syndrome, is active but no longer recruiting, sponsored by Boston Children's Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

In this study, investigators will study the impact of a 1:1 caregiver coaching intervention using the JASPER (Joint Attention, Symbolic Play, Engagement, Regulation) behavioral therapy curriculum compared to a psychoeducational curriculum that will be provided to caregivers for self-directed learning. Investigators want to determine the impact of both interventions on the child's development and behavior, and caregiver implementation of strategies.

Primary Outcome

Joint engagement and joint attention skills will be coded from Caregiver-Child Interaction (CCX) video recordings. The 15-minute CCX videos measure the amount of time that caregiver and child engage during a play session. The frequency of the child's engagement states will be coded using an Engagement State Coding Scheme to measure proportion of video during which child is maintaining Joint Engagement (shared engagement in a play routine).

Conditions Studied

Interventions

  • BEHAVIORAL JASPER
  • BEHAVIORAL Psychoeducational Curriculum

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2023-01-23
Est. Completion 2025-08
Phase NA
Boston Children's Hospital

462 total trials

What the registry record for NCT05638412 still lists

NCT05638412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Down Syndrome appearing as the primary indexed condition, and to 2 interventions - of which JASPER is the first listed.

NCT05638412 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05638412 about?

NCT05638412 is a clinical study titled "Investigating the Impact of JASPER Behavioral Therapy in Children With Down Syndrome". In this study, investigators will study the impact of a 1:1 caregiver coaching intervention using the JASPER (Joint Attention, Symbolic Play, Engagement, Regulation) behavioral therapy curriculum compared to a psychoeducational curriculum that will be provided to caregivers for self-directed learnin...

What is the current status of trial NCT05638412?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 57 participants. The study started on 2023-01-23. Estimated completion is 2025-08.

What conditions does trial NCT05638412 study?

This clinical trial studies the following conditions: Down Syndrome.

What interventions are being tested in trial NCT05638412?

The interventions under investigation include: JASPER (BEHAVIORAL), Psychoeducational Curriculum (BEHAVIORAL).

Who is sponsoring clinical trial NCT05638412?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05638412 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Down Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05638412's enrollment target sits among peer trials

57 33rd of 54 higher than 21 of 54 other Down Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Down Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05638412, the US trial registry maintained by the National Library of Medicine. NCT05638412 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.